Continuous Glucose Monitoring for Prediabetes

(G3 Trial)

This trial tests a new method to help individuals with prediabetes (higher than normal blood sugar levels) avoid developing type 2 diabetes. Participants will wear a continuous glucose monitor (CGM) on their arm to track blood sugar levels. Initially, participants cannot see their glucose levels, but later, they will receive feedback through a smartphone app. Individuals aged 35 or older with prediabetes who are willing to wear a CGM sensor may be suitable for this study. The goal is to use this technology to enhance daily blood sugar control and prevent diabetes. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could prevent diabetes and improve health outcomes.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that using a continuous glucose monitor (CGM) is generally safe for most people. Studies indicate that CGMs can greatly enhance the quality of life for individuals with diabetes by boosting their confidence in managing blood sugar levels. For those with prediabetes, CGMs might offer similar benefits by helping to track and control blood sugar before it reaches diabetic levels.

Regarding safety, many studies have found CGMs to be well-tolerated. Specifically, one study found a significant reduction in severe low blood sugar episodes (hypoglycemia) after participants began using CGMs. This finding suggests that CGMs are not only safe but may also help prevent dangerous drops in blood sugar.

Continuous Glucose Monitoring (CGM) is unique because it offers a proactive approach to managing prediabetes by providing real-time data on glucose levels. Unlike traditional methods like periodic blood tests or finger pricks, CGM continuously tracks glucose, allowing for more precise monitoring and potentially quicker lifestyle adjustments. Researchers are particularly excited about the trial's innovative approach, which includes a phase where participants can see their glucose data live. This real-time visibility can empower individuals to make immediate decisions about diet and activity, potentially preventing the progression to full-blown diabetes.

Research has shown that Continuous Glucose Monitoring (CGM) can improve blood sugar control. Regular CGM users often experience a small but significant drop in hemoglobin A1c levels, a key measure of long-term blood sugar control. For instance, one study found a reduction of about 0.32% in these levels. Another study demonstrated significant improvements in A1c levels compared to those who do not use CGM. For individuals with prediabetes, this can lower the risk of developing type 2 diabetes. Overall, CGM use allows individuals to monitor their glucose levels more closely, potentially leading to better health outcomes.